Underlying data for 'Serum Leucine-Rich Alpha-2 Glycoprotein Levels in Rheumatoid Arthritis and Spondyloarthritis: A Promising Biomarker'

This is a database of a cross-sectional data collected to evaluate serum leucine-rich alpha-2 glycoprotein levels in rheumatoid arthritis and spondyloarthritis. The subjects were recruited from the rheumatology polyclinic of Dr. Cipto Mangunkusumo National Central Public Hospital (Jakarta, Indonesia) from March to May of 2022. This study has received approval from the Research Ethics Committee of Faculty of Medicine Universitas Indonesia and Dr. Cipto Mangunkusumo National Central Public Hospital (KET-197/UN2.F1/ETIK/PPM.00.02/2022). Patients aged over 18 years old with confirmed seropositive active rheumatoid arthritis, ankylosing spondylitis, and peripheral spondyloarthritis who gave their consent were recruited. Patients with other systemic autoimmune diseases, acute infectious diseases, liver disorders, and malignancies are excluded from the study. Patient characteristics, serum LRG (Human LRG ELISA Assay Kit, Immuno-Biological Laboratories Co., Ltd., Fujioka, Gunma, Japan; read with spectrophotometry at 450 nm), and serum CRP (cobas c 311 analyzer, Roche Holding AG, Basel, Switzerland) were recorded in this database.本数据集为用于评估类风湿关节炎与脊柱关节炎患者血清富亮氨酸α2糖蛋白（serum leucine-rich alpha-2 glycoprotein, LRG）水平的横断面研究数据库。研究对象于2022年3月至5月间，从印度尼西亚雅加达西普托·曼昆库苏莫国家中央公立医院风湿内科门诊招募。本研究已获得印度尼西亚大学医学院研究伦理委员会及西普托·曼昆库苏莫国家中央公立医院的伦理审查批准（批准号：KET-197/UN2.F1/ETIK/PPM.00.02/2022）。本研究纳入年龄≥18岁、经确诊且签署知情同意书的血清阳性活动性类风湿关节炎、强直性脊柱炎及外周型脊柱关节炎患者；排除合并其他系统性自身免疫疾病、急性感染性疾病、肝脏疾病及恶性肿瘤的受试者。本数据库收录了受试者的临床特征、血清LRG水平（采用日本群马县藤冈市免疫生物实验室株式会社（Immuno-Biological Laboratories Co., Ltd.）生产的人LRG ELISA检测试剂盒，以450nm波长分光光度法读取检测结果）以及血清C反应蛋白（C-reactive protein, CRP）水平（采用瑞士巴塞尔罗氏控股股份有限公司（Roche Holding AG）cobas c 311分析仪检测）。